Transaction · 0001193125-26-414500

Crystal Adam

Crystal Adam, PRES, R, D, reported an open-market or private sale at Tango Therapeutics, Inc. involving 26400.000000 shares for an estimated $645604.08. Reported holdings after the transaction were 116343.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SPRES, R, D
TNGXTango Therapeutics, Inc.
Filing timeOct 05
Trade dateOct 01, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position traded18.49%Shares sold ÷ (holdings after + shares sold). Estimated position before: 142,743 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$23.08
Pre-filing
1mo ago +7.0%1w ago +6.7%1d ago +8.1%
Returns since
7d30d90d180d1y

TNGX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
TNGX since 2026-10-05Filed 2 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-414500
Common Stock
Transaction date
Oct 01, 2026
Filed Oct 05, 2026, 09:36 PM · 4d delay
Shares
26.4k sh
$24.45 per share
Estimated value
-$645k
Computed from shares × price
Holdings after
116k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership Large Sale 10b5-1 Detected
-4score
Filing-only score

-4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President, R&D

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.

  2. F2

    Represents the weighted average sales price per share. The shares sold at prices ranging from $23.96 to $24.95 per share. Full information regarding the number of shares sold at each price shall be pr…

  3. F3

    Represents the weighted average sales price per share. The shares sold at prices ranging from $25.04 to $25.41 per share. Full information regarding the number of shares sold at each price shall be pr…

  4. F4

    This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.

Original filing · 0001193125-26-414500
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

TNGX